加快STXBP1和SYNGAP1疾病的治疗开发和临床试验准备
Nicolas Marotta1, Michael J Boland2, Benjamin L Prosser3
1Department of Biochemistry and Molecular Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Center for Epilepsy and Neurodevelopmental Disorders (ENDD), University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Physiology, Pennsylvania Muscle Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Current problems in pediatric and adolescent health care
|March 12, 2024
概括
针对神经发育障碍 (NDD) 的基因向疗法正在出现. 本综述侧重于STXBP1和SYNGAP1疾病,从科学和家长的角度讨论其特征,生物学和治疗发展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 基因向疗法为神经发育障碍 (NDD) 提供了新的希望.
- 和神经发育障碍中心 (ENDD) 正在积极开发STXBP1和SYNGAP1疾病的治疗方法.
研究的目的:
- 审查STXBP1和SYNGAP1疾病的临床特征.
- 突出STXBP1和SYNGAP1蛋白质的生物学作用.
- 讨论当前的治疗发展和致病机制.
主要方法:
- 临床特征和生物作用的文献综述.
- 对致病机制的当前研究进行分析.
- 讨论正在进行的治疗开发策略.
主要成果:
- STXBP1和SYNGAP1对神经元功能至关重要.
- 了解它们的作用是开发向治疗的关键.
- 在确定治疗目标和策略方面取得了进展.
结论:
- 基因向疗法在STXBP1和SYNGAP1疾病中表现有前途.
- 需要多学科的方法来应对临床和基础科学的挑战.
- 科学家和家长的独特观点为未来的研究方向提供了信息.
相关概念视频
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


